Verastem (VSTM) to Post Quarterly Earnings on Thursday

Verastem (NASDAQ:VSTM) is projected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Verastem to announce earnings of ($0.46) per share and revenue of $22.8790 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Verastem Trading Up 2.1%

VSTM opened at $5.81 on Wednesday. The firm’s fifty day moving average is $4.75 and its two-hundred day moving average is $5.38. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.00 and a current ratio of 3.04. The firm has a market cap of $510.52 million, a PE ratio of -2.15 and a beta of 0.26. Verastem has a twelve month low of $3.43 and a twelve month high of $11.24.

Analyst Upgrades and Downgrades

Several analysts have commented on VSTM shares. Royal Bank Of Canada set a $14.00 target price on shares of Verastem and gave the stock an “outperform” rating in a report on Tuesday, July 7th. BTIG Research reiterated a “buy” rating and issued a $18.00 price target on shares of Verastem in a report on Thursday, July 2nd. Mizuho lowered their price objective on shares of Verastem from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Alliance Global Partners restated a “buy” rating on shares of Verastem in a report on Friday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Verastem in a research report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Verastem currently has an average rating of “Moderate Buy” and a consensus price target of $14.40.

Insiders Place Their Bets

In other news, CEO Dan Paterson sold 20,871 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $4.18, for a total transaction of $87,240.78. Following the completion of the transaction, the chief executive officer directly owned 591,242 shares of the company’s stock, valued at $2,471,391.56. This trade represents a 3.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.94% of the stock is currently owned by company insiders.

Institutional Trading of Verastem

A number of institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC grew its position in Verastem by 78.2% in the first quarter. AQR Capital Management LLC now owns 62,603 shares of the biopharmaceutical company’s stock valued at $377,000 after purchasing an additional 27,477 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Verastem by 236.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 756,402 shares of the biopharmaceutical company’s stock valued at $4,561,000 after buying an additional 531,873 shares during the last quarter. Geode Capital Management LLC lifted its position in Verastem by 24.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,199,259 shares of the biopharmaceutical company’s stock worth $4,978,000 after buying an additional 238,995 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Verastem by 19.2% during the 2nd quarter. Rhumbline Advisers now owns 59,553 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 9,594 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Verastem by 40.0% during the 2nd quarter. Invesco Ltd. now owns 52,063 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 14,879 shares during the last quarter. Institutional investors own 88.37% of the company’s stock.

About Verastem

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.